Search

Your search keyword '"Ahlenstiel G"' showing total 267 results

Search Constraints

Start Over You searched for: Author "Ahlenstiel G" Remove constraint Author: "Ahlenstiel G"
267 results on '"Ahlenstiel G"'

Search Results

1. Interferon-λ3 Exacerbates the Inflammatory Response to Microbial Ligands: Implications for SARS-CoV-2 Pathogenesis

2. The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals

4. Global multi-stakeholder endorsement of the MAFLD definition

6. Monitoring quality of care in hepatocellular carcinoma: A modified Delphi consensus

7. The psychometric properties of the grazing questionnaire in an obesity sample with and without binge eating disorder.

12. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics.

13. Final challenges: real-world experience with sofosbuvir, velpatasvir and voxilaprevir in patients with advanced cirrhosis.

14. Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients with Difficult to Cure Characteristics

15. Australia IBD Microbiome (AIM) Study: protocol for a multicentre longitudinal prospective cohort study.

21. Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis

22. Efficacy and safety of sofosbuvir/velpatasvir/voxilaprevir for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics.

29. Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis

34. Efficacy and safety of sofosbuvir, velpatasvir, and voxilaprevir in NS5A-experienced patients with advanced liver disease or prior liver transplantation: The first Australian real-world experience.

35. Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis

36. CD147 mediates intrahepatic leukocyte aggregation and determines the extent of liver injury.

38. Tissue-based activation of mucosal-associated invariant T (MAIT) cells in combination ipilimumab and nivolumab checkpoint inhibitor (CI) colitis

39. Cover Image

42. FibroGENE: A gene-based model for staging liver fibrosis

44. IFNL3/4 genotype is associated with altered immune cell populations in peripheral blood in chronic hepatitis C infection

45. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease

46. FibroGENE: A gene-based model for staging liver fibrosis

47. Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease

49. A Summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses

50. Carman, W F see Jazayeri, M. Carnot, F see Lebray, P. Caronia, S, McGarvey, M J, Goldin, R D &. Foster, G R. Negative correlation between intrahepatic expression of hepatitis C antigens and apoptosis despite high-level expression of Fas

Catalog

Books, media, physical & digital resources